Oxygen Biotherapeutics Announces Formation of Steering Committee for Phase 3 LEVO-CTS Trial of Levosimendan

By: via Benzinga
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.